Adagrasib is a novel targeted therapy designed to inhibit the KRAS G12C mutation, which is a common genetic alteration found in various types of cancer. This mutation leads to the continuous activation of the KRAS protein, promoting uncontrolled cell growth and proliferation. Adagrasib is a small molecule that selectively binds to and inhibits the mutant KRAS G12C protein, thereby blocking its oncogenic activity.
